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Abstract
A missense single nucleotide polymorphism (SNP) in the immune modulatory gene IL1A has
been associated with ovarian cancer risk (rs17561). While the exact mechanism through which
this SNP alters risk of ovarian cancer is not clearly understood, rs17561 has also been associated
with risk of endometriosis, an epidemiologic risk factor for ovarian cancer. IL-1α is both regulated
by and able to activate NF-κB, a transcription factor family that induces transcription of many
pro-inflammatory genes and may be an important mediator in carcinogenesis. We therefore tagged
SNPs in over 200 genes in the NF-κB pathway for a total of 2,282 SNPs (including rs17561) for
genotype analysis of 15,604 cases of ovarian cancer in patients of European descent, including
6,179 of high grade serous (HGS), 2,100 endometrioid, 1,591 mucinous, 1,034 clear cell and
1,016 low grade serous (LGS), including 23,235 control cases spanning 40 studies in the Ovarian
Cancer Association Consortium (OCAC). In this large population, we confirmed the association
between rs17561 and clear cell ovarian cancer (OR=0.84, 95% CI: 0.76–0.93; p=0.00075), which
remained intact even after excluding participants in the prior study (OR=0.85, 95% CI: 0.75–0.95;
p=0.006). Considering a multiple-testing-corrected significance threshold of p< 2.5×10−5, only
one other variant, the TNFSF10 SNP rs6785617, was associated significantly with a risk of
ovarian cancer (low malignant potential (LMP) tumors OR=0.85, 95% CI: 0.79–0.91; p=0.00002).
Our results extend the evidence that borderline tumors may have a distinct genetic etiology.
Further investigation of how these SNPs might modify ovarian cancer associations with other
inflammation related risk factors is warranted.
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INTRODUCTION
Inflammation is a known mediator of carcinogenesis and a number of risk factors associated
with ovarian cancer are also linked to inflammatory processes (1). The inverse relationship
between parity (2, 3) and oral contraceptive (OC) use (3–6) and ovarian cancer risk is
thought to be due to increased ovulations in women with fewer pregnancies or shorter
duration of OC use. The damage and repair cycle associated with each ovulation recruits
immune mediators with potential to promote ovarian cancer initition and growth (1, 7).
Evidence for a relationship between pelvic inflammatory disease (PID) and ovarian cancer
risk has also been observed in a few studies (8, 9). Furthermore, endometriosis, another
condition associated with elevated inflammatory markers (10), has been found to increase
risk of clear-cell, invasive endometrioid, and low-grade serous tumors (11). Studies of
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perineal talcum powder use additionally suggest an association with ovarian cancer risk
(12), presumably due to its pro-inflammatory properties (13). Use of nonsteroidal anti-
inflammatory drugs (NSAIDs) has also been linked to reduced risk of ovarian cancer,
particularly aspirin use in invasive ovarian cancer risk (14, 15).
In a previous study by our group, interrogation of SNPs in several inflammation-related
genes revealed an association between ovarian cancer risk and SNPs in IL1A and ALOX5
(16); most notable was a missense SNP in IL1A, rs17561, which had the strongest
associations with the rarer histologic subtypes. IL-1α, the cytokine encoded by this gene,
mediates a number of inflammatory and immune responses, including response to tissue
injury (17, 18). In the present study, we assessed this SNP for overall and histologic subtype
associations in a much larger population of ovarian cancer cases and controls to evaulate
replication. We additionally investigated SNPs in other NF-κB pathway genes, as IL-1α is
not only produced following NF-κB activation (19), but signaling of IL-1α through its
receptor results in downstream activation of NF-κB (20), which leads to transcription of a
number of genes whose products promote inflammation (21).
In addition to the prior association, there is strong biological support for further study of
polymorphisms in the NF-κB pathway in ovarian cancer (21). This pathway appears to play
a crucial role in the process that links inflammation to cancer (22). Activation of this family
of transcription factors leads to transcription and expression of a number of pro-
inflammatory cytokines (23) with the ability to promote tumor growth (24). Specifically,
activation of NF-κB through IKKε was shown to be associated with more aggressive
behavior in ovarian cancer cell lines (25). Additionally, NF-κB activation can inhibit
apoptosis (26). Finally, NF-κB activation has been associated with aberrant cellular
activities in endometriosis (27). Therefore, we expanded our investigation of inflammation-
related SNPs to include variants in over 200 NF-κB pathway related genes in a large
collection of ovarian cancer patients and controls from the Ovarian Cancer Association
Consortium (OCAC).
METHODS
Study participants
Participants from 40 OCAC studies of primarily European ancestry were included in this
project (28). For nine studies that were case-only (GRR, HSK, LAX, ORE, PVD, RMH,
SOC, SRO, UKR), cases were pooled with case-control studies from the same geographic
region, resulting in 31 total case-control sets. Study characteristics are summarized in
Supplementary Table 1 and the number of cases by histological subtype is shown in
Supplementary Table 2. A total of 47,092 women were included.
SNP selection
As reviewed previously (21), we identified a number of genes known to encode NF-κB
subunits or molecules key to NF-κB activation (in signaling cascade), inhibition (inhibitory
role), degradation (involved in proteasomal degradation), and nuclear function (nuclear
proteins involved in transcription) and narrowed the list to the top 210 most important genes
in the pathway. In early 2010, tagSNPs within 5 kb of these genes with r2≥0.8 and
MAF≥0.05 in European individuals were identified using the most informative source for
each gene from among HapMap Project Phase II Release 24 (29), the 1000 Genomes Project
Low-coverage Pilot(30), SeattleSNPs (31), Innate Immunity PGA(32), and NIEHS
SNPs(33). Additional putative-functional SNPs were also included, regardless of linkage
disequilibrium (LD), with European MAF ≥0.05 which were 1 kb upstream, non-
synonymous or resided in a 3’ UTR, 5’ UTR, splice site, or miRNA binding site (34, 35).
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We used SNPPicker (36) to optimally pick tagSNPs for each gene. SNPs which had an
Illumina design score <0.4 or which were in LD (r2>0.80) with a SNP found to be null (p
>0.05) in prior analysis of genome-wide association study (GWAS) data (28) were
excluded. Genes and coverage are shown in Supplementary Table 3.
Genotyping and Quality Control
Genotyping of study samples and duplicates, as previously described (28), was carried out as
part of a large custom Illumina Infinium iSelect BeadChip (over 200,000 SNPs) at McGill
University and Génome Québec (n=19,806) and the Mayo Clinic Medical Genome Facility
(n=28,820) on 96-well plates containing 750 ng genomic DNA (or 1,500 ng whole-genome
amplified DNA). Along with OCAC samples, HapMap samples for European (CEU, n=60),
African (YRI, n=53) and Asian (JPT+CHB, n=88) populations were also genotyped. Raw
intensity data files were reviewed for centralized quality control, and genotypes were called
using GenCall (37),which showed superior performance over Illuminus (38) and GenoSNP
(39) upon manual inspection of representative SNPs.
SNPs were excluded according to the following criteria: (1) no genotype call; (2)
monomorphism; (3) call rate less than 95 percent and MAF > 0.05 or call rate less than 99
percent with MAF < 0.05; (4) evidence of deviation from Hardy-Weinberg equilibrium (p <
10−7) in controls; (5) greater than 2 percent discordance in duplicate pairs. Overall, 94.5
percent of SNPs passed QC; a total of 2,282 NF-κB SNPs were included in analyses.
SNP data were generated on 47,092 unique samples. We used identity-by-state to identify
first-degree relative pairs, of which we excluded the one with the lowest call rate. Additional
samples were excluded according to the following criteria: 1) call rates < 95 percent; 2)
heterozygosity > five standard deviations from the intercontinental ancestry specific mean
heterozygosity; 3) ambiguous sex; 4) lowest call rate from a first-degree relative pair; 5)
missing case-control status; 6) missing age at diagnosis; 7) non-epithelial cancer, unknown
if epithelial cancer or missing histology; 8) Brenner tumors; 9) <90 European ancestry based
on LAMP (40). After the above exclusions, a total of 38,839 subjects including 15,604 cases
(13,727 invasive) and 23,235 controls were retained for analysis (Supplementary Table 4).
Statistical methods
SNP genotypes were coded as 0, 1, or 2 based on the number of copies of the minor allele.
Associations with risk of ovarian cancer were evaluated first using cases combined, and then
within strata defined by tumor behavior [low malignant potential (LMP) and invasive] and
histology [low grade serous (LGS), high grade serous (HGS), mucinous, endometrioid, and
clear cell]. We used a subset of 37,000 non-NF-κB markers to perform principal component
(PC) analysis within the European subset in order to account for potential residual
population stratification (41). For all analyses, SNPs were modeled using a one degree-of-
freedom linear term assuming a log-additive, or ordinal, effect. Odds ratios (OR), 95%
confidence intervals (CI) and p-values were generated using logistic regression analysis in
PLINK (Version 1.07) (42) with adjustment for age, study site, and the first five European
PCs as described above. Effect modification by site and epidemiologic risk factors were
tested using interaction terms and differences in risk by subtype were tested using
multicategorical (polytomous) regression.
SNPs reported in Tables 1–3, were additionally tested for confounding by the following
epidemiologic risk factors in the subset of study sites with information on each
epidemiologic variable: acetaminophen use [non-regular (<1×/week), regular (≥1×/week)],
aspirin use [non-regular (<1×/week), regular (≥1×/week)], non-aspirin NSAID use [non-
regular (<1×/week), regular (≥1×/week)], young adult body mass index (BMI) [continuous
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(age 18 or 20 years)], recent BMI [continuous (one or five years prior to diagnosis)], history
of endometriosis (yes, no), history of breast or ovarian cancer in a first-degree relative
(none, one or more relatives), age at menarche (≤11, >11 years), menopausal status at
diagnosis (pre/peri, post), ever use of oral contraceptives (yes, no), and ever use of estrogen
after age 50 (yes, no). None of these variables changed the estimates by more than 10% for
any of the SNPs with sufficient numbers in the subsets to calculate stable estimates.
Pairwise LD among controls was estimated using PLINK (42). Results (−log10(p-value)) for
regions of interest were visualized using LocusZoom (Standalone Version) (43), which
included user-specified LD as defined above. The SNP examined in a previous study, IL1A
rs17561, was re-evaluated in this study for replication purposes using a nominal p-value of
0.05. We used a modified Bonferroni adjusted critical value to determine statistical
significance of all other newly studied NFKB SNPs. To account for LD between SNPs, a qr
decomposition of the SNP genotype matrix (44) was used to determine the effective number
of independent tests. Genotypes for 2282 NF-κB pathway SNPs with a MAF > 0.01 from a
random sample of 1000 epithelial ovarian cancer cases and 1000 controls were considered.
The number of independent tests (i.e. the rank of the SNP genotype matrix) was determined
to be 2000, thus yielding a Bonferroni adjusted critical value of 2.5 × 10−5 (0.05/number of
independent tests).
RESULTS
Replication of IL1A SNP rs17561 in ovarian cancer risk
The missense SNP, rs17561, in the IL1A gene, previously reported by our group to be
significantly associated with clear cell, mucinous, and endometrioid ovarian cancer risk in a
subset of OCAC studies (3972 cases and 3043 controls) (16), was reevaluated using a larger
number of participants (15,604 cases and 23,235 controls). This included 6,179 HGS, 2,100
endometrioid, 1,591 mucinous, 1,034 clear cell, and 1,016 LGS ovarian cancer cases. In this
larger pooled study, we found no association between rs17561 and risk of all ovarian cancer;
however, when we stratified by histologic subtype, we found modest inverse associations
with the minor allele of this SNP and risk of endometrioid (OR=0.93, 95% CI: 0.87–1.00;
p=0.053) and mucinous subsets (OR=0.91, 95% CI: 0.84–0.98; p=0.018) and a stronger
inverse association with the minor allele of this SNP and clear cell ovarian cancer
(OR=0.84, 95% CI: 0.76–0.93; p=0.00075) (Figure 1). As the previous report of rs17561
describing an association with clear cell (N=283 cases) ovarian cancer included a subset of
the current study population (16), we restricted our analysis to exclude all participants from
the prior study and found that the inverse association between the minor allele of this SNP
and risk of clear cell (N=734 cases) disease remained (OR=0.85, 95% CI: 0.75–0.95;
p=0.006).
The major allele of rs17561 has also recently been reported to be associated with increased
risk of endometriosis in a pooled Japanese case-control study (45). History of endometriosis
was obtained for several studies in OCAC via self-report. Given the link between
endometriosis and clear cell ovarian cancer (11), we chose to assess the association between
endometriosis and rs17561 in the European ancestry OCAC population, where we observed
the association between this SNP and clear cell ovarian cancer. While we found a trend in
the direction of decreased risk of endometriosis with the minor allele of rs17561 (OR=0.93,
95% CI: 0.82–1.05) among the 10,759 controls with available genotype and endometriosis
information, it was not statistically significant (p=0.25).
We additionally evaluated whether any of the epidemiologic risk factors for ovarian cancer
listed in Supplementary Table 5 modified the association between rs17561 and risk of clear
cell ovarian cancer. There was little evidence for interaction between rs17561 and any of
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these factors, with the exception of a modest interaction with NSAID use (p=0.046). When
stratified by NSAID use, the inverse association between rs17561 and clear cell ovarian
cancer risk was observed among regular NSAID users (OR=0.71, 95% CI: 0.54–0.95), but
null among non-regular NSAID users (OR=1.01, 95% CI: 0.84–1.20).
Overall ovarian cancer risk associations with NF-κB pathway SNPs
A total of 2,281 additional SNPs in 210 genes in the NF-κB were also analyzed. When
ranked by p-value, the most significant SNPs in the NF-κB pathway found to be associated
with overall (includes LMP) ovarian cancer risk at p<0.005 were located in CARD11,
FBXW7, IL1RAPL2, IRAK2, MAP3K14, NFKB1, PRKCA, TAF3, TLR7, TNFRSF1B, and
TNFSF10 genes (Table 1); however, none of these SNPs reached statistical significance
after multiple testing correction. A CARD11 SNP rs74302019 had the lowest p-value
(OR=1.07, 95% CI: 1.03–1.10; p= 8.9110−05), and four out of 57 SNPs tagged in CARD11
were associated with ovarian cancer risk at p<0.005, although rs41324349 and rs41483047
were in moderate LD with rs74302019 with r2 = 0.61 and 0.41, respectively.
Tumor behavior associations with NF-κB pathway SNPs
We also assessed NF-κB pathway SNPs according to tumor behavior (invasive or LMP). All
SNPs associated with tumor behavior at p<0.005 are reported in Table 2. SNPs in
IL1RAPL2, OTUD7B, PLCG1, TAF4, TLR5, TNFSF10, and TRAF2 were suggestively
associated with LMP ovarian tumors at p<0.005. One SNP in TNFSF10 was statistically
significantly associated with LMP risk after adjustment for multiple testing, rs6785617
(OR=0.85, 95% CI: 0.79–0.91; p=2.0 × 10−5). We further evaluated this association for
effect modification by epidemiologic risk factors previously reported in association with
ovarian cancer, but we found little evidence for interaction (Supplementary Table 5).
No NF-κB pathway SNPs were associated with risk of invasive ovarian cancer at p<2.5 ×
10−5. However, the SNP associated with risk of invasive ovarian cancer with the lowest p-
value was rs7071113 (OR=1.06, 95% CI: 1.02–1.10; p=0.00087) in TAF3 and suggestive
associations were observed at p<0.005 for other SNPs in TAF3 as well as CARD11, FBXW7,
IL1RN, IRAK2, MAP3K7, TAB2, PRKDC, and TNFRSF1B.
Histologic subtype associations with NF-κB pathway SNPs
While no SNPs were associated with risk at the corrected level of 2.5×10−5 for any
histologic subtypes (Table 3), the missense SNP rs17561 (reported above) in the IL1A gene,
was the NF-κB pathway SNP that had the lowest p-value in association with clear cell
ovarian cancer risk (OR=0.84, 95% CI: 0.76–0.93; p= 0.00075); four other IL1A SNPs,
rs1800587, rs1304037, rs2856836, and rs1800794 were also inversely associated with
ovarian cancer risk at p<0.005 as expected based on near complete LD with rs17561
(r2>0.99). Other SNPs that were suggestively associated with clear cell ovarian cancer at
p<0.005 were found in AKT1, BCL10, CD3E, IKBKE, IL1RN, NFKBIZ, PPARG, TLR3, and
TLR7. For endometrioid ovarian cancer MTOR SNP, rs12129467, had the lowest p-value
with a suggestive association (OR=1.19, 95% CI: 1.07–1.33; p= 0.0013); this SNP was the
only tagSNP in this gene of 10 genotyped with p<0.005 (data not shown). Other SNPs with
potential associations for endometrioid ovarian cancer risk at p<0.005 were found in the
F2R, IKBKAP, and HNRNPAB genes. Mucinous ovarian cancer was potentially (p<0.005)
associated with SNPs in CD247, IL1A, PRKCA, PRKCQ, PRKCZ, PTPN13, TLR1, TLR10,
and TNFSF10. The SNP with the lowest p-value was rs34251715, an intronic SNP in
PRKCA (OR=0.88, 95% CI: 0.82–0.96; p= 0.0028).
The SNPs suggestively associated with risk of high-grade serous ovarian cancer at p<0.005
were in located in AARB2, CARD11, IL1RN, MAP3K14, PIK3R1, PRKCA, PRKCZ,
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PRKDC, TLR5, and TNFRSF1B. CARD11 SNP rs71527417 had the lowest p-value for HGS
ovarian cancer risk (OR=0.87, 95% CI: 0.80–0.95; p= 0.0015), although the association was
not significant at the multiple comparisons threshold. Two other SNPs in this gene,
rs74302019 and rs41324349, were also associated with HGS, at p<0.005 and the association
was in the opposite direction (LD with rs71527417: r2=0.03 and 0.05, respectively). For
LGS ovarian cancer risk, the association with the lowest p-value was with intronic SNP,
rs3136646, located in NFKBIB (OR=0.81, 95% CI: 0.72–0.91; p=0.00034). Additional
possible associations with LGS at p<0.005 included SNPs from GSK3B, IKBKAP, and
PRKCA.
DISCUSSION
In this large study of 15,604 ovarian cancer cases and 23,235 controls of European descent,
we assessed the rs17561 SNP, previously found by our group to be associated with overall
ovarian cancer risk. When analyzed by histologic subtypes, there were modest associations
with risk of mucinous and endometrioid subtypes and a fairly strong association with risk of
clear cell, all of which are consistent with our previous study (16). The clear cell association
remained even after exclusion of participants in the prior report. In this same large study
population, assessment of additional variants in over 200 genes in the NF-κB pathway
pointed to some suggestive associations with ovarian cancer risk. The most significant SNPs
associated with each subtype tended to fall in different genes. However, with the exception
of rs6785617 and LMP tumors, none of these SNPs reached our critical p-value of 2.5×10−5.
The missense SNP in IL1A, rs17561, results in an amino acid change at position 114 from
alanine (major allele) to serine (minor allele). Enhanced cleavage of the IL-1α precursor
(46) has been reported to be the functional consequence of a serine residue at this position
and calpain cleaved IL-1α appears to bind IL-1R1 with higher affinity, resulting in higher
cytokine expression than the uncleaved form (47). The major allele (A) of rs17561, has
recently been reported to be associated with increased susceptibility to endometriosis in two
independent case-control studies in a Japanese population (45). This is consistent with our
finding in the present study that the minor allele is associated with decreased risk of clear
cell ovarian cancer, and is especially interesting given the previous associations found
between endometriosis and clear cell ovarian cancer (11), suggesting a potential shared
biological mechanism. When we evaluated this SNP for association with endometriosis in
the European ancestry OCAC population, we saw little evidence for an association between
rs17561 and endometriosis. The lack of association in the OCAC population could
potentially be attributed to other genetic differences between Japanese and European
ancestry populations. However, we also note that in the present study we are limited by
questionnaire-based self-reported history of endometriosis, while the Japanese study used
clinical imaging or biopsy confirmation to ascertain diagnosis of endometriosis.
Recently, Trabert et al reported a statistically significant association between regular aspirin
use and a modest non-significant association with non-aspirin NSAID use and decreased
risk of invasive ovarian cancer in the OCAC population (15). Interestingly, we find that the
association between rs17561 and clear cell risk appears to be modified by non-aspirin
NSAID use, where the inverse association with the minor allele is found among regular
NSAID users but is null in non-regular NSAID users. The role of IL-1α on tumor
development is complex; depending on whether it has been processed, whether it is
membrane-bound or secreted, and which stage in tumorigenesis and cell type it is expressed,
it may play a role in immune surveillance or tumor progression (48). One potential
mechanism through which NSAIDs may influence the effects of IL-1α on tumor growth is
through inhibition of prostaglandin synthesis by COX-2 (49), which is expressed following
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IL-1α signalling through IL-1R1. NSAID use has also been reported to interact with IL1
SNP haplotypes in risk of B-cell non-Hodgkin lymphoma (50).
TNFSF10, also known as TRAIL, induces a signaling cascade that leads to apoptosis upon
binding either of its cognate death receptors, DR4 and DR5 (51). This ligand has been of
particular interest for use in cancer therapy, as many cancer cell types are more sensitive to
TNFSF10 induced cell death than normal cells (52). TRAIL is also important in immune
surveillance of tumor cells (53) and plays a role in controlling inflammation by inducing
apoptosis in macrophages (54) and neutrophils (55). The only novel NF-κB SNP to pass our
significance threshold was TNFSF10 SNP, rs6785617, in association with LMP tumor
behavior. This SNP falls 4.5 kb downstream of this gene and to our knowledge it has not
previously been reported to be associated with ovarian tumors or other conditions, nor have
consequences of this SNP on expression or function been tested experimentally.
CARD11 is an intermediate protein that assists in NF-κB activation following B or T cell
receptor complex ligation (56–58) or activation of NK cell receptors (59). CARD11 intronic
SNPs, rs74302019, rs41324349, or rs41483047 are in moderate LD with each other and had
the lowest p-values associated with overall ovarian cancer risk. To our knowledge none of
the have been previously assessed for associations with ovarian cancer or other conditions
and their consequences on CARD11 function or expression are unclear. Although aberrant
expression in tumors is possible, CARD11, also known as CARMA1, is normally expressed
in cells of hematopoietic origin (60) suggesting that the role of this polymorphism in ovarian
cancer risk may be related to tumor surveillance by immune cells.
This study has several strengths, the most notable of which is the very large sample size
which provided greater power than all previous candidate gene studies in ovarian cancer to
detect associations between this disease and SNPs with lower MAF. We also had greater
power to assess associations between the rare subtypes: endometrioid, clear cell, and
mucinous ovarian cancer. We used a SNP tagging approach to comprehensively cover genes
in the NF-κB pathway; however the study was limited by lack of coverage of some genes,
mostly due to loss of SNPS that failed QC. Nonetheless, this is the first study to extensively
assess variation in genes involved in NF-κB activition, including signaling, inhibition,
degradation, and nuclear function in association with ovarian cancer risk. Because of
variation in MAF by race, we restricted our analysis to participants of genetic European
descent, which reduces confounding but also generalizability to other populations. Because
only one SNP was associated with risk of LMP tumors below the multiple test corrected p-
value, we cannot rule out that any of the suggestive associations were actually false
positives.
In conclusion, this large study of NF-κB pathway genes in relation to risk of ovarian cancer
risk found several SNPs with suggestive associations that varied by histology and tumor
behavior. All SNP associations were modest, but most interesting were the replication of
IL1A SNP, rs17561, in clear cell risk and the association between TNFSF10 SNP,
rs6785617, and LMP ovarian cancer. Future investigations of interactions between these
polymorphisms and environmental factors, the role they play on tumor phenotypes, and how
they affect NF-κB activity in different cell types are needed to better understand the
mechanism by which they might be contributing to ovarian cancer pathogenesis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
IL1A SNP, rs17561, associations with risk of ovarian cancer by subtype. Forest plots of OR
and 95% CI for HGS (high grade serous), LGS (low grade serous), mucinous, endometrioid,
clear cell and overall ovarian cancer.
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